Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Shin JS, Huh YS
A Phase 1 clinical trial of the MOTS-C analog CB4211 found the compound safe after 7 days of dosing, though persistent mild injection site bumps were noted
NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760 ERIC HAROLD YECIES (Chief Legal Officer & GC) sold 15,000 shares for an estimated $183,750 To track insider transactions, check out Quiver Quantitative's insider trading dashboard
It could represent a new treatment option for AUD, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms
Combining genetic predisposition insight with comprehensive medication reconciliation creates a more complete clinical picture
US$ 29.66
US$ 26.68
US$ 24.87
US$ 20.88
US$ 27.95
-1775582746855.png&w=3840&q=75)
US$ 26.43
.jpg)
US$ 26.07
US$ 28.37
US$ 23.84
US$ 20.43
